KRSA · Korsana Biosciences, Inc.
$30.22
+0.11 (+0.37%)
At close · Oct 29
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$20.21M
Shares
668,764
Volume · Oct 29
138.99K
Avg daily vol (37 sessions)
114.65K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$30.22
Open$29.50
Day$29.50–31.02
52W close$7.56–44.66
Avg vol 30d128K
Short int24K · 3.6% float · 1.0d
Short vol21%
Last earningsApr 1, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.90M
Trailing 12 months
Net income (TTM)
−$6.71M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-359.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+38.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.6%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
−3%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
61%
mid-range
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+39%
trailing
YTD return
+240%
this year
Relative strength
+35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
2 of 21 funds reported for Sep 30 · net +1 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.56% of float · ▲ +106.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
21 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
EPS growth
+8%
Y/Y
Free cash flow
$-3.3M
Quant / Vol
risk profile
Volatility
328%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
61%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $31 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
2 of 21 funds reported for Sep 30 · net +1 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.56% of float · ▲ +106.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
21 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $30 · 61%
Range high $45
vs 200-day avg +38%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRSA
this stock
Korsana Biosciences, Inc.
|
$20.21M | — | +3.7% | — | 3.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.50B | +19.1% | +46.2% | 31.4 | 1.7% |
|
MRNA
Moderna, Inc.
|
$88.93B | +655.4% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.33B | +6.1% | +20.8% | 18.1 | 2.1% |
|
CSLLY
Csl Ltd
|
$67.18B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
DEF 14A
- Filed
- Oct 15, 2026
- This year
- 17
Korsana Biosciences, Inc. will seek approval on November 13, 2026 to redomesticate from Massachusetts to the Cayman Islands. A prior proposal received approximately 61.8% of votes cast but failed on August 26, 2026, and is now resubmitted with unanimous board support.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRSA | -9.6% | -3.1% | +39.3% | -5.6% | +239.9% |
| SPY | +0.7% | +0.7% | +4.3% | +0.9% | +12.8% |
| vs SPY | -10.3% | -3.8% | +35.0% | -6.4% | +227.1% |